

Online Resource 6 Patient baseline characteristics

Parameter	Bimatoprost SR 6 µg (n = 18)	Bimatoprost SR 10 µg (n = 21)	Bimatoprost SR 15 µg (n = 21)	Bimatoprost SR 20 µg (n = 15)
Mean age (range), years	60.4 (27–76)	65.4 (52–77)	63.2 (21–83)	63.4 (34–82)
Male, n (%)	6 (33.3)	12 (57.1)	11 (52.4)	8 (53.3)
Race, n (%)				
White	10 (55.6)	15 (71.4)	17 (81.0)	11 (73.3)
Black	3 (16.7)	4 (19.0)	2 (9.5)	3 (20.0)
Other	5 (27.8)	2 (9.5)	2 (9.5)	1 (6.7)
Baseline IOP at hour 0, mm Hg, mean ± SD				
Study eye (Bimatoprost SR)	25.1 ± 3.6	24.5 ± 2.1	25.1 ± 3.0	26.6 ± 4.1
Fellow eye (topical bimatoprost 0.03%)	24.4 ± 3.8	24.1 ± 2.1	24.2 ± 3.3	25.5 ± 4.0
Iris color in study eye, n (%)				
Dark (brown or dark brown)	13 (72.2)	10 (47.6)	10 (47.6)	7 (46.7)
Light (any other color)	5 (27.8)	11 (52.4)	11 (52.4)	8 (53.3)
Lens status (both eyes), n (%)				
Phakic	14 (77.8)	14 (66.7)	8 (38.1)	9 (60.0)
Pseudophakic	4 (22.2)	7 (33.3)	13 (61.9)	6(40.0)
CECD in study eye, cells/mm ² , mean (SD)	2712.6 (256.1)	2691.3 (175.7)	2663.4 (180.2)	2738.7 (171.9)
CCT, µm, mean (SD)				
Study eye	552.1 (43.8)	536.6 (45.8)	562.3 (39.3)	559.7 (41.4)
Fellow eye	559.4 (38.1)	550.0 (58.0)	568.8 (38.2)	572.4 (74.5)

Bimatoprost SR bimatoprost sustained-release implant, *CCT* central corneal thickness, *CECD* corneal endothelial cell density, *IOP* intraocular pressure, *SD* standard deviation